Lazar David E.'s Form 4 filing
Bio Green Med Solution, Inc. (BGMS) · filed Feb 28, 2025
- Accession no.
- 0000921895-25-000651
- Filed
- Feb 28, 2025, 4:48 PM ET
- Trade date
- Feb 26, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $5.51M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lazar David E.CIK 0001932843 | Officer (Interim CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2025 | Common Stock | MOption exerciseAcquired | +2,650,000 | –F2 | – | 2,650,000 | Direct | |
| Feb 26, 2025 | Common Stock | MOption exerciseAcquired | +191,978,820 | –F4 | – | 194,628,820 | Direct | |
| Feb 26, 2025 | Common Stock | SSaleDisposed | −194,628,820 | $0.0283F5 | −$5,507,995.61 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The shares of Series C Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
Referenced by the price of 1 transaction in Table I.
- F4
The shares of Series D Preferred Stock are convertible at the option of the Reporting Person for no additional consideration.
Referenced by the price of 1 transaction in Table I.
- F5
On February 26, 2025, the Reporting Person sold 194,628,820 shares of Common Stock in a private transaction for total consideration of $5,500,000.
Referenced by the price of 1 transaction in Table I.
- F7
At a closing on January 6, 2025, the Reporting Person acquired 1,000,000 shares of Series C Preferred Stock from the Company for a total purchase price of $1,000,000. Each share of Series C Preferred Stock is convertible into 2.65 shares of the Company's Common Stock at any time.
Referenced by the price of 1 transaction in Table II.
- F9
At a closing on February 6, 2025, the Reporting Person acquired 2,100,000 shares of Series D Preferred Stock from the Company for a total purchase price of $2,100,000. Each share of Series D Preferred Stock is convertible into 110 shares of the Company's Common Stock at any time.
Referenced by the price of 1 transaction in Table II.